BRBS vs BRK-B
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BRBS exhibits significant financial fragility, evidenced by a mediocre Piotroski F-Score of 4/9 and a current price ($3.58) that significantly exceeds both its Graham Number ($3.02) and its Intrinsic Value ($0.77). The company is struggling with negative revenue growth (-2.80% YoY) and an alarmingly low ROE of 3.29%, indicating poor capital efficiency. Most critically, the reported dividend yield of 68.18% is mathematically unsustainable and represents a classic 'dividend trap' given the company's profitability profile. Technical trends are entirely bearish (0/100), and long-term price performance is dismal with a 5-year decline of nearly 70%.
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
Compare Another Pair
Related Comparisons
BRBS vs BRK-B: Head-to-Head Comparison
This page compares Blue Ridge Bankshares, Inc. (BRBS) and Berkshire Hathaway Inc. (BRK-B) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.